This biomarker is also known as:
- cystatin A (stefin A),
- cystatin AS,
View in BioMuta
CSTA, or cystatin-A, is a member of the cystatin superfamily, which includes proteins that contain multiple cystatin-like sequences. Some members of the cystatin superfamily are active cysteine protease inhibitors, of which there are three families: type 1 cystatins (stefins), type 2 cystatins, and kininogens. CSTA is a stefin that functions as a cysteine protease inhibitor, forming tight complexes with papain and the cathepsins B, H, and L. Stefins have been proposed as prognostic and diagnostic biomarkers for cancer.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Studies have demonstrated an inverse relationship between increased cathepsin B expression and decreased CSTA in a variety of human tumors. Studies suggest that CSTA is one of the promising candidate biomarkers for lung cancer and deserves further investigation in lung tumorigenesis.
CSTA belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.